Financials in USD. Standardized financial statements.
A compact view of how Sonnet BioTherapeutics Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.00M | $18,626 | $147,805 | $349,943 | $483,626 | $0 | $40.61M | $30.73M | $41.43M | $41.70M |
| Revenue Growth? | +5268.8% | -87.4% | -57.8% | -27.6% | 0.0% | -100.0% | +32.1% | -25.8% | -0.6% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $93,257 | $0 | $58,313 | $7.93M | $29.94M | $39.41M | $38.38M |
| Gross Profit? | $0 | $18,626 | $147,805 | -$21.09M | $483,626 | -$58,313 | $32.68M | $791,106 | $2.03M | $3.33M |
| Gross Margin? | 0.0% | +100.0% | +100.0% | -6027.9% | +100.0% | 0.0% | +80.5% | +2.6% | +4.9% | +8.0% |
| Operating Expenses? | $16.84M | $11.87M | $18.94M | $8.58M | $25.57M | $17.41M | $4.71M | $3.86M | $4.55M | $5.95M |
| Operating Income? | -$15.84M | -$11.85M | -$18.79M | -$29.67M | -$25.09M | -$17.41M | -$4.71M | -$3.07M | -$2.52M | -$2.62M |
| EBITDA? | -$15.84M | -$11.77M | -$18.72M | -$29.58M | -$24.99M | -$24.24M | -$13.15M | -$3.71M | -$2.93M | $541,147 |
| Income Before Tax | -$15.79M | -$7.44M | -$18.83M | -$29.72M | -$24.98M | -$24.27M | -$4.87M | -$8.07M | -$7.81M | -$4.15M |
| Income Tax Expense | -$218,400 | $0 | $0 | $0 | $0 | $0 | $162,873 | -$701,224 | -$644,429 | $198,463 |
| Net Income? | -$16.11M | -$7.44M | -$18.83M | -$29.77M | -$25.01M | -$24.27M | -$4.87M | -$6.85M | -$6.79M | -$9.08M |
| EPS? | $-3.95 | $-11.35 | $-145.12 | $-1203.05 | $-2507.83 | $-17159.00 | $-163753.00 | $-126904.00 | $-175138.00 | $-269068.00 |
| Diluted EPS? | $-3.95 | $-11.35 | $-145.12 | $-1203.05 | $-2507.83 | $-17159.00 | $-163753.00 | $-126904.00 | $-175138.00 | $-269068.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality